Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
Medicine has been trending towards personalization for decades. The growth of individualized medicine and new diagnostic technologies has resulted in drugs that are tailored towards patients’ profile and condition—and are much more effective as a result. These therapies rely on the existence of molecular tests, including genetic testing, predictive and prognostic biomarkers, and companion diagnostics.
But how well are payers keeping up with this sea change? How are they managing new brands that utilize molecular testing to identify patient cohorts? How…
We are in the midst of a weight-loss drug explosion. Mania for Novo Nordisk’s Wegovy/Ozempic has taken hold of both celebrities and everyday patients, leading to massive shortages and a surge of interest in all glucagon-like peptide 1 (GLP-1) agonists. Industry experts say that obesity has become a top five global market driver, and MMIT’s sister company, Evaluate, estimates the obesity opportunity as exceeding $35 billion by 2028.
The propensity for weight-loss drugs to induce a swell of public enthusiasm is…
According to the American Society of Health-System Pharmacists (ASHP), U.S. drug shortages are the highest they’ve been in more than two decades. As of the end of 2024’s first quarter, 323 drugs were in short supply, including many chemotherapy, ADHD, and pain and sedation medications. These drugs run the gamut from basic drugs to life-saving therapies, and are predominantly generics, with 46% of the quarter’s new shortages being injectables.
While drug shortages are a well-documented issue across the globe, pressure has…
In the shift toward value-based care, more payers are outsourcing the management of specific therapeutic areas to third-party specialty benefit managers (SBMs). These companies help payers manage high-cost, high-complexity disease states by leveraging provider networks and making coverage recommendations intended to improve outcomes and lower cost.
What does the growing prevalence of SBMs mean for pharma companies? To find out, MMIT’s Biologics & Injectables Index team conducted research with 35 payers covering 116 million commercial lives. We found that payers representing…
Manufacturers engage with managed care organizations (MCOs) in a number of ways, from deep conversations regarding clinical indications and brand coverage to general sessions focused on product portfolios and overall business. Although pharma companies have historically engaged with payers in phase III of the drug development lifecycle, pharma/payer meetings are now shifting to earlier in the timeline, during phase I and phase II.
From a pharma company’s perspective, the goal for payer meetings is to ensure that a product’s clinical and…
Pharma companies share product messaging with providers in a myriad of ways, from email campaigns to social media to next-best-action marketing, print and online media, and industry conferences. Despite the rise of omni-channel marketing, in-person meetings are still a crucial means of communicating a brand’s value, efficacy, and competitive differentiators to healthcare professionals (HCPs).
Of course, it has become increasingly difficult to access HCPs, as many are unwilling to meet with pharmaceutical sales reps. According to the Veeva Pulse Field Trends…
At the beginning of May, almost 8,000 attendees descended on Las Vegas for Asembia’s AXS24 Summit. While all of the session speakers discussed the future of healthcare in one way or another, MMIT noticed a few common trends about the state of the industry today.
If you missed the conference, read on for an overview of three key areas, along with a few of our thoughts:
IRA Sharpens Focus on Maximizing Drug Lifecycle Revenue Since the passing of the Inflation Reduction…
Navigating the landscape of patient access in the pharma industry has become increasingly complex, extending far beyond traditional channels. The challenges are multifaceted, influenced by evolving policies, innovative payer strategies, and shifts in provider dynamics.
Recent market research conducted by MMIT and The Dedham Group, encompassing insights from more than 300 industry stakeholders, sheds light on the critical barriers to patient access that are top of mind for pharma executives. Let’s take a look at the results of our survey:
1.…
Despite the rapid evolution of personalized medicine, access to genetic testing and next-generation sequencing (NGS) is a challenge—due in no small part to coverage confusion. Physicians struggle to navigate poorly defined testing coverage policies and a fragmentated payer and vendor ecosystem, resulting in delayed care for patients requiring precision therapies.
While biomarker testing and NGS are more likely to be covered by payers if markers are associated with targeted therapies (i.e., biomarker-specific language in a drug’s indication statement), challenges persist for…
The hypertension market is no stranger to new entrants, with therapies ranging from calcium channel blockers and angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors and beta blockers. As a mature market, generics are widely available, and many of the more recently approved therapies are combinations of existing agents or different formulations of FDA-approved treatments.
So in a market with long-established therapies and plenty of branded and generic competition, do new market entrants stand a chance? And what does…
